Announced

Completed

Peak Bio went public via a SPAC merger with Ignyte Acquisition in a $378m deal.

Synopsis

Peak Bio, a clinical-stage biopharmaceutical company, went public via a SPAC merger with Ignyte Acquisition, a blank cheque company, in a $378m deal. “We believe that Peak Bio is now well positioned to succeed in the public markets and look forward to updating the entire investment community on our progress in our differentiated approach in both oncology and rare inflammatory diseases,” Hoyoung Huh, Peak Bio Chairman and Founder.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US